❖ Orchard Therapeutics Publishes Gene Therapy OTL-101 for the Treatment of ADA-SCID Phase 1/2 Clinical Trial Data Data from a Phase 1/2 clinical trial in patients with combined immunodeficiency (ADA-SCID) were published in the New England Journal of Medicine (NEJM). Results of the trial showed that patients had a 100% survival rate for 2-3 years after receiving a single gene therapy treatment, and more than 95% of patients did not need other treatments to control their disease. This long-term efficacy result demonstrates the potential of gene therapy to functionally cure rare genetic diseases, the press release noted.
Source: WuXi PharmaTech
❖ New coronavirus Accurate and complete gene annotation map completed After the genomics research, they drew the most accurate and complete gene annotation map of the new coronavirus to date, confirmed several protein-coding genes, and found that some genes did not encode any proteins. In addition, they analyzed nearly 2,000 mutations produced by different strains of the new coronavirus, allowing them to better assess the importance of these mutations.
Source: Science and Technology Daily
❖ Jiang Rui/ Wang Yongxiong team published a deep learning method for single-cell data analysis in Nature sub-journal
May 10, Jiang Rui team from Tsinghua University Automation Department and Stanford The team of Wing Hung Wong from the Department of Statistics of of the University jointly published an article entitled Simultaneous deep generative modelling and clustering of single-cell genomic data in Nature Machine Intelligence, proposing a new single-cell data analysis method scDEC. The theoretical basis of the
scDEC method is the neural network probability density estimation theory Roundtrip proposed by the team earlier for high-dimensional data (Liu et al, Proc Natl Acad Sci USA, 118(15):e2101344118, 2021). Guided by this theory, scDEC cleverly uses a set of generative adversarial networks to map high-dimensional single-cell data to a low-dimensional latent space, perform cluster analysis in the low-dimensional space, and then use another set of generative adversarial networks. The network maps low-dimensional data back to a high-dimensional space. Through the reciprocating cycle and co-optimization of such two sets of generative adversarial networks, scDEC integrates the identification of cell types and the dimensionality reduction, generation, and batch effect removal of single-cell data, not only realizing the fusion of single-cell gene expression and chromosome opening The identification of cell types based on sex data has also been successfully applied to downstream cell function modeling studies such as inference of cell developmental trajectory and analysis of intracellular gene regulation mechanisms.
Source: Sequencing China
Paper link:
https://www.nature.com/articles/s42256-021-00333-y
❖ West Lake University Tao Liang’s team identified the host of Clostridium knowlesi alpha toxin for the first time Receptor
On May 10, Tao Liang's team from West Lake University published a research paper online entitled "Sulfated glycosaminoglycans and low-density lipoprotein receptor mediate the cellular entry of Clostridium novyi alpha-toxin" in Cell Research. A guided KO screen identified the sulfated glycosaminoglycan as a key attachment factor for Tcnα. Sulfated glycosaminoglycans are ubiquitous on the cell surface and thus serve as ideal landing sites for a variety of infectious agents, including the emerging virus SARS-COV-2 that caused a global pandemic.
This study further revealed that the synergistic effect between sulfated glycosaminoglycans and LDLR family members contributes to the entry of Tcnα. Finally, this study demonstrates that sulfated glycosaminoglycans are key attachment factors for Tcnα-induced myopathy in vivo, and that SCD effectively reduces Tcnα-induced tissue damage in a mouse model. These findings suggest that blocking the interaction between Tcnα and sulfated glycosaminoglycans may be a new strategy for developing potential therapies for Tcnα-induced diseases.
来源：iNature
参考消息：
https://www.nature.com/articles/s41422-021-00510-z
❖ 基因编程公司Ginkgo Bioworks通过反向收购上市估值150亿美元
5月11日， Biotech unicorn Ginkgo Bioworks announced an agreement with SPAC company Soaring Eagle Acquisition to go public through a reverse takeover. The rationale behind the
Ginkgo business is that biology can be "programmed" in a computer-like fashion, simply by sequencing the four basic chemical building blocks (ACGTs) of using DNA. The company can engineer mammalian, bacterial and yeast cells for specific purposes. To help alleviate the shortage of diagnostic tests during the pandemic, Ginkgo has also repurposed technology to read and modify living cells.
Source: Financial Associated Press
❖ AIGene editing treatment company West Lake Yungu has completed tens of millions of angel rounds of financing
Recently, West Lake Yungu Zhiyao (Hangzhou) Gene Technology announced that it has completed tens of millions of angel rounds of financing. Gaorong Capital Investment. This round of financing is mainly used to accelerate the development of the company's artificial intelligence technology in the field of gene editing therapy, and to promote the establishment of the company's core R&D platform for CRISPR therapy.
Focusing on gene editing therapy, West Lake Cloud Valley is developing cutting-edge technology iteratively based on high-throughput Biotech data output and deep learning model building, and is building an original technology-driven gene editing therapy development platform, AIdit, and is committed to artificial intelligence technology The whole process of landing in the field of gene therapy.
Source: Interface News
❖ Fei Dean passed the on-site review of ISO15189 Pathology and New Coronary Nucleic Acid Detection Extension
Recently, Hefei Dean Medical Laboratory successfully passed the ISO15189 quality system organized by China National Accreditation Service for Conformity Assessment (CNAS) The on-site review of "Supervision Review + Item Expansion" successfully expanded 14 items this time, including 13 pathology items and new crown nucleic acid testing items.
As the focus of this expanded review, Hefei Dean Pathology Laboratory has previously participated in the inter-laboratory quality control of immune tissue chemical antibodies organized by the National Pathology Quality Control Center and China Medical Device Industry Association Pathology Professional Committee. And obtained the "National Inter-laboratory Quality Evaluation Certificate of Immunohistochemistry", "2020 Gastric Cancer Her2 Immunohistochemistry Inter-laboratory Quality Evaluation Certificate", and "2020 Breast Cancer Her2 Immunohistochemistry Inter-laboratory Quality Evaluation Certificate".
Source: Dean Diagnostics
All reprinted articles in this official account are for the purpose of transmitting more information, and the source and author are clearly indicated. Media or individuals who do not wish to be reprinted can contact us ([email protected]) , we will delete it immediately. All articles represent the author's point of view only and do not represent the position of the party.
The above pictures are all from the Internet. If there is any infringement, please contact to delete.
